Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
NeOnc Technologies Holdings, Inc. ( (NTHI) ) has provided an announcement.
Between January 29 and April 20, 2026, NeOnc Technologies Holdings, Inc. executed a series of four securities purchase agreements to issue common stock and accompanying five-year warrants at per-share prices of $7.20 and $9.00, respectively. Across multiple closings with institutional and other investors, the company raised several million dollars, with offerings under the first two agreements ending on January 31 and February 28, and the third and fourth scheduled to terminate on April 30, 2026.
Under the third and fourth agreements signed on March 20 and April 20, 2026, NeOnc issued a combined 416,666 shares and the same number of warrants for proceeds of about $3 million, while leaving capacity for additional issuances before the April 30 cutoff. The company stated it will use the net proceeds from these private, unregistered offerings to fund preclinical trials of its NEO216 candidate and committed to file a resale registration statement for the shares and warrant shares from the fourth agreement, underscoring its push to finance early-stage oncology development.
The most recent analyst rating on (NTHI) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on NeOnc Technologies Holdings, Inc. stock, see the NTHI Stock Forecast page.
Spark’s Take on NTHI Stock
According to Spark, TipRanks’ AI Analyst, NTHI is a Neutral.
The score is held down primarily by weak financial performance (large losses, accelerating cash burn, and negative equity) and bearish technicals (below key moving averages with negative MACD). Corporate events provide some offset via financing and clinical milestones, while valuation metrics are limited by negative earnings and no dividend.
To see Spark’s full report on NTHI stock, click here.
More about NeOnc Technologies Holdings, Inc.
NeOnc Technologies Holdings, Inc. is a biotechnology company focused on developing oncology therapies, including its NEO216 drug candidate. The company operates in the biopharmaceutical sector, targeting funding and partnerships to advance preclinical and clinical development of its cancer treatment pipeline.
Average Trading Volume: 50,422
Technical Sentiment Signal: Strong Sell
Current Market Cap: $119.3M
Learn more about NTHI stock on TipRanks’ Stock Analysis page.